BridgeBio Pharma (BBIO) director awarded RSUs and stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma director Eric Aguiar received new equity awards. On June 22, 2026, he was granted 3,990 restricted stock units, each representing one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the stock options vest in full on June 22, 2027, as long as he continues serving on the board through that date. After these awards, he holds 10,579 shares of common stock directly, plus the 5,277 options expiring on June 21, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
AGUIAR ERIC
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,277 | $0.00 | -- |
| Grant/Award | Common Stock | 3,990 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,277 shares (Direct, null);
Common Stock — 10,579 shares (Direct, null)
Footnotes (1)
- Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Key Figures
RSUs granted: 3,990 units
Stock options granted: 5,277 options
Option exercise price: $68.92/share
+3 more
6 metrics
RSUs granted
3,990 units
Restricted stock units granted on June 22, 2026
Stock options granted
5,277 options
Director stock option award on June 22, 2026
Option exercise price
$68.92/share
Conversion or exercise price for granted options
Common shares after award
10,579 shares
Total common stock held directly after transactions
Option expiration
June 21, 2036
Expiration date of 5,277 stock options
Vesting date
June 22, 2027
Full vesting for RSUs and option-underlying shares
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 68.9200."
exercise price financial
"conversion_or_exercise_price: "68.9200" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The RSUs vest in full on June 22, 2027, subject to continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
FAQ
What insider transaction did BridgeBio Pharma (BBIO) report for Eric Aguiar?
BridgeBio Pharma reported that director Eric Aguiar received equity awards on June 22, 2026. He was granted 3,990 restricted stock units and 5,277 stock options as part of his compensation, rather than buying or selling shares on the open market.
How many BridgeBio Pharma (BBIO) RSUs were granted to Eric Aguiar?
Eric Aguiar received 3,990 restricted stock units from BridgeBio Pharma. Each RSU represents a contingent right to receive one share of common stock, subject to vesting conditions tied to his continued service on the company’s board of directors through June 22, 2027.
What are the terms of Eric Aguiar’s BridgeBio Pharma (BBIO) stock options?
Aguiar was granted 5,277 stock options with a $68.92 exercise price. These options give him the right to buy BridgeBio common shares at that price, vesting in full on June 22, 2027, and expiring on June 21, 2036 if not exercised earlier.
When do Eric Aguiar’s BridgeBio (BBIO) RSUs and options vest?
Both the 3,990 restricted stock units and the 5,277 option-underlying shares vest in full on June 22, 2027. Vesting requires Aguiar to continue serving on BridgeBio Pharma’s board of directors through that vesting date, according to the award terms.
Under which plan were Eric Aguiar’s BridgeBio (BBIO) RSUs granted?
The restricted stock units were granted under BridgeBio Pharma’s 2021 Amended and Restated Stock Option and Incentive Plan. This plan governs equity-based compensation, including RSUs and stock options, for directors and other eligible participants at the company.